La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Nurix Therapeutics Gestione
Gestione criteri di controllo 4/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Arthur Sands
Amministratore delegato
US$4.4m
Compenso totale
Percentuale dello stipendio del CEO | 13.5% |
Mandato del CEO | 10yrs |
Proprietà del CEO | 0.5% |
Durata media del management | 4.2yrs |
Durata media del Consiglio di amministrazione | 4yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares
Sep 07Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data
Sep 04Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans
Jul 15Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case
Jun 19What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You
May 29Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
Apr 15Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues
Apr 14Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet
Feb 20Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now
Jan 16Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Dec 29Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues
Oct 14Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher
Oct 13Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Sep 30Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts
Apr 18We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Apr 15We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate
Nov 28Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M
Oct 06Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M
Jul 07FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.
Jun 30We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Jun 21We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth
Mar 07Nurix: Advancing Targeted Protein Modulation Therapies
Nov 21Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth
Nov 21We're Not Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn
Jul 24Nurix Therapeutics appoints new operations chief
Jun 21Analisi delle retribuzioni degli amministratori delegati
Data | Compenso totale | Stipendio | Guadagni aziendali |
---|---|---|---|
May 31 2024 | n/a | n/a | -US$165m |
Feb 29 2024 | n/a | n/a | -US$145m |
Nov 30 2023 | US$4m | US$591k | -US$144m |
Aug 31 2023 | n/a | n/a | -US$149m |
May 31 2023 | n/a | n/a | -US$157m |
Feb 28 2023 | n/a | n/a | -US$179m |
Nov 30 2022 | US$9m | US$572k | -US$180m |
Aug 31 2022 | n/a | n/a | -US$171m |
May 31 2022 | n/a | n/a | -US$154m |
Feb 28 2022 | n/a | n/a | -US$135m |
Nov 30 2021 | US$5m | US$539k | -US$117m |
Aug 31 2021 | n/a | n/a | -US$99m |
May 31 2021 | n/a | n/a | -US$89m |
Feb 28 2021 | n/a | n/a | -US$63m |
Nov 30 2020 | US$17m | US$521k | -US$43m |
Aug 31 2020 | n/a | n/a | -US$37m |
May 31 2020 | n/a | n/a | -US$21m |
Feb 29 2020 | n/a | n/a | -US$24m |
Nov 30 2019 | US$1m | US$474k | -US$22m |
Compensazione vs Mercato: La retribuzione totale di Arthur ($USD 4.36M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 5.62M ).
Compensazione vs guadagni: La retribuzione di Arthur è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Arthur Sands (62 yo)
10yrs
Mandato
US$4,363,120
Compensazione
Dr. Arthur T. Sands, M.D., Ph D., has been the Chief Executive Officer and Director of Nurix Therapeutics, Inc. (formerly, Nurix Inc.) since September 2014 and has been its President since June 2020. Dr. S...
Gruppo dirigente
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
CEO, President & Director | 10yrs | US$4.36m | 0.48% $ 7.1m | |
Chief Financial Officer | 8.5yrs | US$1.61m | 0.048% $ 714.6k | |
Chief Scientific Officer | 4.3yrs | US$1.63m | 0.070% $ 1.0m | |
Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
Senior Accounting Manager | no data | Nessun dato | Nessun dato | |
Chief Technical Officer | less than a year | Nessun dato | Nessun dato | |
Chief Legal Officer | 5yrs | US$1.65m | 0.038% $ 566.9k | |
Chief People Officer | 2.1yrs | Nessun dato | Nessun dato | |
Chief Business Officer | 4.2yrs | Nessun dato | Nessun dato | |
Senior VP & Head of Early Drug Discovery | 3.7yrs | Nessun dato | Nessun dato |
4.2yrs
Durata media
58yo
Età media
Gestione esperta: Il team dirigenziale di NRIX è considerato esperto (durata media dell'incarico 4.1 anni).
Membri del Consiglio di amministrazione
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
CEO, President & Director | 10yrs | US$4.36m | 0.48% $ 7.1m | |
Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
Independent Chairman | 5.1yrs | US$238.29k | 0% $ 0 | |
Member of Medical Advisory Board | 1.7yrs | Nessun dato | Nessun dato | |
Independent Director | 2.9yrs | US$225.79k | 0% $ 0 | |
Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
Independent Director | 5.2yrs | US$228.29k | 0% $ 0 | |
Independent Director | 8.4yrs | US$263.29k | 0.052% $ 768.3k | |
Independent Director | 2.9yrs | US$225.79k | 0% $ 0 | |
Independent Director | 2yrs | US$223.29k | 0% $ 0 |
4.0yrs
Durata media
67.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NRIX sono considerati esperti (durata media dell'incarico 3.9 anni).